Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 508 entries
Sorted by: Best Match Show Resources per page
DA Negatively Regulates IGF-I Actions Implicated in Cognitive Function via Interaction of PSD95 and nNOS in Minimal Hepatic Encephalopathy.

Frontiers in cellular neuroscience

Ding S, Zhuge W, Wang X, Yang J, Lin Y, Wang C, Hu J, Zhuge Q.
PMID: 28932186
Front Cell Neurosci. 2017 Sep 06;11:258. doi: 10.3389/fncel.2017.00258. eCollection 2017.

Insulin-like growth factor I (IGF-I) has been positively correlated with cognitive ability. Cognitive decline in minimal hepatic encephalopathy (MHE) was shown to be induced by elevated intracranial dopamine (DA). The beneficial effect of IGF-I signaling in MHE remains unknown....

Cite
Ding S, Zhuge W, Wang X, et al. DA Negatively Regulates IGF-I Actions Implicated in Cognitive Function via Interaction of PSD95 and nNOS in Minimal Hepatic Encephalopathy. Front Cell Neurosci. 2017;11:258doi: 10.3389/fncel.2017.00258.
Ding, S., Zhuge, W., Wang, X., Yang, J., Lin, Y., Wang, C., Hu, J., & Zhuge, Q. (2017). DA Negatively Regulates IGF-I Actions Implicated in Cognitive Function via Interaction of PSD95 and nNOS in Minimal Hepatic Encephalopathy. Frontiers in cellular neuroscience, 11258. https://doi.org/10.3389/fncel.2017.00258
Ding, Saidan, et al. "DA Negatively Regulates IGF-I Actions Implicated in Cognitive Function via Interaction of PSD95 and nNOS in Minimal Hepatic Encephalopathy." Frontiers in cellular neuroscience vol. 11 (2017): 258. doi: https://doi.org/10.3389/fncel.2017.00258
Ding S, Zhuge W, Wang X, Yang J, Lin Y, Wang C, Hu J, Zhuge Q. DA Negatively Regulates IGF-I Actions Implicated in Cognitive Function via Interaction of PSD95 and nNOS in Minimal Hepatic Encephalopathy. Front Cell Neurosci. 2017 Sep 06;11:258. doi: 10.3389/fncel.2017.00258. eCollection 2017. PMID: 28932186; PMCID: PMC5592740.
Copy Download .nbib Format: NLM
Insulin-like growth factor (IGF)-I and IGF binding proteins axis in diabetes mellitus.

Annals of pediatric endocrinology & metabolism

Kim MS, Lee DY.
PMID: 26191509
Ann Pediatr Endocrinol Metab. 2015 Jun;20(2):69-73. doi: 10.6065/apem.2015.20.2.69. Epub 2015 Jun 30.

Increasing evidence suggests an important role of the insulin-like growth factor (IGF)-IGF binding protein (IGFBP) axis in the maintenance of normal glucose and lipid metabolism. Significant changes occur in the local IGF-I-IGFBPs environment in response to the diabetic milieu....

Cite
Kim MS, Lee DY. Insulin-like growth factor (IGF)-I and IGF binding proteins axis in diabetes mellitus. Ann Pediatr Endocrinol Metab. 2015;20(2):69-73doi: 10.6065/apem.2015.20.2.69.
Kim, M. S., & Lee, D. Y. (2015). Insulin-like growth factor (IGF)-I and IGF binding proteins axis in diabetes mellitus. Annals of pediatric endocrinology & metabolism, 20(2), 69-73. https://doi.org/10.6065/apem.2015.20.2.69
Kim, Min Sun, and Lee, Dae-Yeol. "Insulin-like growth factor (IGF)-I and IGF binding proteins axis in diabetes mellitus." Annals of pediatric endocrinology & metabolism vol. 20,2 (2015): 69-73. doi: https://doi.org/10.6065/apem.2015.20.2.69
Kim MS, Lee DY. Insulin-like growth factor (IGF)-I and IGF binding proteins axis in diabetes mellitus. Ann Pediatr Endocrinol Metab. 2015 Jun;20(2):69-73. doi: 10.6065/apem.2015.20.2.69. Epub 2015 Jun 30. PMID: 26191509; PMCID: PMC4504992.
Copy Download .nbib Format: NLM
Growth hormone therapy for Prader-willi syndrome: challenges and solutions.

Therapeutics and clinical risk management

Grugni G, Sartorio A, Crinò A.
PMID: 27330297
Ther Clin Risk Manag. 2016 Jun 02;12:873-81. doi: 10.2147/TCRM.S70068. eCollection 2016.

Prader-Willi syndrome (PWS) is characterized by a dysregulation of growth hormone (GH)/insulin-like growth factor I axis, as the consequence of a complex hypothalamic involvement. PWS' clinical picture seems to resemble the classic non-PWS GH deficiency (GHD), including short stature,...

Cite
Grugni G, Sartorio A, Crinò A. Growth hormone therapy for Prader-willi syndrome: challenges and solutions. Ther Clin Risk Manag. 2016;12:873-81doi: 10.2147/TCRM.S70068.
Grugni, G., Sartorio, A., & Crinò, A. (2016). Growth hormone therapy for Prader-willi syndrome: challenges and solutions. Therapeutics and clinical risk management, 12873-81. https://doi.org/10.2147/TCRM.S70068
Grugni, Graziano, et al. "Growth hormone therapy for Prader-willi syndrome: challenges and solutions." Therapeutics and clinical risk management vol. 12 (2016): 873-81. doi: https://doi.org/10.2147/TCRM.S70068
Grugni G, Sartorio A, Crinò A. Growth hormone therapy for Prader-willi syndrome: challenges and solutions. Ther Clin Risk Manag. 2016 Jun 02;12:873-81. doi: 10.2147/TCRM.S70068. eCollection 2016. PMID: 27330297; PMCID: PMC4898426.
Copy Download .nbib Format: NLM
Cross-Talk between Adiponectin and IGF-IR in Breast Cancer.

Frontiers in oncology

Mauro L, Naimo GD, Ricchio E, Panno ML, Andò S.
PMID: 26236690
Front Oncol. 2015 Jul 15;5:157. doi: 10.3389/fonc.2015.00157. eCollection 2015.

Obesity is a chronic and multifactorial disorder that is reaching epidemic proportions. It is characterized by an enlarged mass of adipose tissue caused by a combination of size increase of preexisting adipocytes (hypertrophy) and de novo adipocyte differentiation (hyperplasia)....

Cite
Mauro L, Naimo GD, Ricchio E, et al. Cross-Talk between Adiponectin and IGF-IR in Breast Cancer. Front Oncol. 2015;5:157doi: 10.3389/fonc.2015.00157.
Mauro, L., Naimo, G. D., Ricchio, E., Panno, M. L., & Andò, S. (2015). Cross-Talk between Adiponectin and IGF-IR in Breast Cancer. Frontiers in oncology, 5157. https://doi.org/10.3389/fonc.2015.00157
Mauro, Loredana, et al. "Cross-Talk between Adiponectin and IGF-IR in Breast Cancer." Frontiers in oncology vol. 5 (2015): 157. doi: https://doi.org/10.3389/fonc.2015.00157
Mauro L, Naimo GD, Ricchio E, Panno ML, Andò S. Cross-Talk between Adiponectin and IGF-IR in Breast Cancer. Front Oncol. 2015 Jul 15;5:157. doi: 10.3389/fonc.2015.00157. eCollection 2015. PMID: 26236690; PMCID: PMC4502352.
Copy Download .nbib Format: NLM
Seasonal changes in circulating growth hormone (GH), hepatic GH-binding and plasma insulin-like growth factor-I immunoreactivity in a marine fish, gilthead sea bream,Sparus aurata.

Fish physiology and biochemistry

Pérez-Sánchez J, Marti-Palanca H, Le Bail PY.
PMID: 24198190
Fish Physiol Biochem. 1994 Jul;13(3):199-208. doi: 10.1007/BF00004358.

We have studied the seasonal relationship between growth and circulating growth hormone (GH), hepatic GH-binding and plasma insulin-like growth factor-I immunoreactivity in gilthead sea bream,Sparus aurata. The seasonal increase in plasma GH levels preceded by several weeks the summer...

Cite
Pérez-Sánchez J, Marti-Palanca H, Le Bail PY. Seasonal changes in circulating growth hormone (GH), hepatic GH-binding and plasma insulin-like growth factor-I immunoreactivity in a marine fish, gilthead sea bream,Sparus aurata. Fish Physiol Biochem. 1994;13(3):199-208doi: 10.1007/BF00004358.
Pérez-Sánchez, J., Marti-Palanca, H., & Le Bail, P. Y. (1994). Seasonal changes in circulating growth hormone (GH), hepatic GH-binding and plasma insulin-like growth factor-I immunoreactivity in a marine fish, gilthead sea bream,Sparus aurata. Fish physiology and biochemistry, 13(3), 199-208. https://doi.org/10.1007/BF00004358
Pérez-Sánchez, J, et al. "Seasonal changes in circulating growth hormone (GH), hepatic GH-binding and plasma insulin-like growth factor-I immunoreactivity in a marine fish, gilthead sea bream,Sparus aurata." Fish physiology and biochemistry vol. 13,3 (1994): 199-208. doi: https://doi.org/10.1007/BF00004358
Pérez-Sánchez J, Marti-Palanca H, Le Bail PY. Seasonal changes in circulating growth hormone (GH), hepatic GH-binding and plasma insulin-like growth factor-I immunoreactivity in a marine fish, gilthead sea bream,Sparus aurata. Fish Physiol Biochem. 1994 Jul;13(3):199-208. doi: 10.1007/BF00004358. PMID: 24198190.
Copy Download .nbib Format: NLM
Insulin-like growth factor- I and factors affecting it in thalassemia major.

Indian journal of endocrinology and metabolism

Soliman AT, De Sanctis V, Elalaily R, Yassin M.
PMID: 25729686
Indian J Endocrinol Metab. 2015 Mar-Apr;19(2):245-51. doi: 10.4103/2230-8210.131750.

Despite improvement of blood transfusion regimens and iron chelation therapy growth and maturational delay, cardiomyopathy, endocrinopathies and osteoporosis still occur in good number of thalassemic patients. Decreased IGF-1 secretion occurs in the majority of the thalassemic patients particularly those...

Cite
Soliman AT, De Sanctis V, Elalaily R, et al. Insulin-like growth factor- I and factors affecting it in thalassemia major. Indian J Endocrinol Metab. 2015;19(2):245-51doi: 10.4103/2230-8210.131750.
Soliman, A. T., De Sanctis, V., Elalaily, R., & Yassin, M. (2015). Insulin-like growth factor- I and factors affecting it in thalassemia major. Indian journal of endocrinology and metabolism, 19(2), 245-51. https://doi.org/10.4103/2230-8210.131750
Soliman, Ashraf T, et al. "Insulin-like growth factor- I and factors affecting it in thalassemia major." Indian journal of endocrinology and metabolism vol. 19,2 (2015): 245-51. doi: https://doi.org/10.4103/2230-8210.131750
Soliman AT, De Sanctis V, Elalaily R, Yassin M. Insulin-like growth factor- I and factors affecting it in thalassemia major. Indian J Endocrinol Metab. 2015 Mar-Apr;19(2):245-51. doi: 10.4103/2230-8210.131750. PMID: 25729686; PMCID: PMC4319264.
Copy Download .nbib Format: NLM
Administration of a Synthetic Peptide Derived from the E-domain Region of Mechano-Growth Factor Delays Decompensation Following Myocardial Infarction.

International journal of cardiovascular research

Shioura K, Pena J, Goldspink P.
PMID: 25606570
Int J Cardiovasc Res. 2014 Jun 24;3(3):1000169. doi: 10.4172/2324-8602.1000169.

Insulin like growth factor-I (IGF-1) isoforms differ structurally in their E-domain regions and their temporal expression profile in response to injury. We and others have reported that Mechano-growth factor (MGF), which is equivalent to human IGF-1c and rodent IGF-1Eb...

Cite
Shioura K, Pena J, Goldspink P. Administration of a Synthetic Peptide Derived from the E-domain Region of Mechano-Growth Factor Delays Decompensation Following Myocardial Infarction. Int J Cardiovasc Res. 2014;3(3):1000169doi: 10.4172/2324-8602.1000169.
Shioura, K., Pena, J., & Goldspink, P. (2014). Administration of a Synthetic Peptide Derived from the E-domain Region of Mechano-Growth Factor Delays Decompensation Following Myocardial Infarction. International journal of cardiovascular research, 3(3), 1000169. https://doi.org/10.4172/2324-8602.1000169
Shioura, Km, et al. "Administration of a Synthetic Peptide Derived from the E-domain Region of Mechano-Growth Factor Delays Decompensation Following Myocardial Infarction." International journal of cardiovascular research vol. 3,3 (2014): 1000169. doi: https://doi.org/10.4172/2324-8602.1000169
Shioura K, Pena J, Goldspink P. Administration of a Synthetic Peptide Derived from the E-domain Region of Mechano-Growth Factor Delays Decompensation Following Myocardial Infarction. Int J Cardiovasc Res. 2014 Jun 24;3(3):1000169. doi: 10.4172/2324-8602.1000169. PMID: 25606570; PMCID: PMC4297642.
Copy Download .nbib Format: NLM
Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients.

Molecular and clinical oncology

Suzuki H, Roa JC, Kawamoto T, Ishige K, Wistuba II, Li D, Thomas MB, Shoda J.
PMID: 26137252
Mol Clin Oncol. 2015 May;3(3):464-470. doi: 10.3892/mco.2015.515. Epub 2015 Feb 25.

Carcinomas of the gallbladder (GBCa) and bile ducts are aggressive tumors with poor survival and it is, therefore, essential to elucidate the molecular mechanisms of the various signaling pathways in order to develop effective therapies. In this study, tumor...

Cite
Suzuki H, Roa JC, Kawamoto T, et al. Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients. Mol Clin Oncol. 2015;3(3):464-470doi: 10.3892/mco.2015.515.
Suzuki, H., Roa, J. C., Kawamoto, T., Ishige, K., Wistuba, I. I., Li, D., Thomas, M. B., & Shoda, J. (2015). Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients. Molecular and clinical oncology, 3(3), 464-470. https://doi.org/10.3892/mco.2015.515
Suzuki, Hideo, et al. "Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients." Molecular and clinical oncology vol. 3,3 (2015): 464-470. doi: https://doi.org/10.3892/mco.2015.515
Suzuki H, Roa JC, Kawamoto T, Ishige K, Wistuba II, Li D, Thomas MB, Shoda J. Expression of insulin-like growth factor I receptor as a biomarker for predicting prognosis in biliary tract cancer patients. Mol Clin Oncol. 2015 May;3(3):464-470. doi: 10.3892/mco.2015.515. Epub 2015 Feb 25. PMID: 26137252; PMCID: PMC4471625.
Copy Download .nbib Format: NLM
Growth Promoting Activity of Chimeric Molecules of "Insulin-Insulin-like Growth Factor-I" .

Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica

Zhang X, Tang YH, Feng YM, Jing NH.
PMID: 12232638
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 1996;28(4):434-437.

The chimeric molecules of "Insulin-Insulin-like Growth Factor-I", Ins/IGFI(8) and Ins/IGF-I(11) were obtained by means of enzymatic semisynthesis. The growth promoting activity of these chimeric molecules were evaluated with a mouse mammary tumor derived cell line, GR2H6, and compared with...

Cite
Zhang X, Tang YH, Feng YM, et al. Growth Promoting Activity of Chimeric Molecules of "Insulin-Insulin-like Growth Factor-I" . Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 1996;28(4):434-437
Zhang, X., Tang, Y. H., Feng, Y. M., & Jing, N. H. (1996). Growth Promoting Activity of Chimeric Molecules of "Insulin-Insulin-like Growth Factor-I" . Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica, 28(4), 434-437.
Zhang, Xin, et al. "Growth Promoting Activity of Chimeric Molecules of "Insulin-Insulin-like Growth Factor-I" ." Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica vol. 28,4 (1996): 434-437.
Zhang X, Tang YH, Feng YM, Jing NH. Growth Promoting Activity of Chimeric Molecules of "Insulin-Insulin-like Growth Factor-I" . Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 1996;28(4):434-437. PMID: 12232638.
Copy Download .nbib Format: NLM
Hormonal evaluation in schizophrenic patients treated with neuroleptics.

Neuro endocrinology letters

Melkersson K, Hulting AL, Hall K.
PMID: 11462115
Neuro Endocrinol Lett. 1999;20(3):199-204.

The aim of this study was to hormonally evaluate schizophrenic patients on long-term treatment with neuroleptics. Twenty-eight patients (14 men and 14 women) on long-term therapy with different neuroleptics were investigated. Blood samples for prolactin (PRL), growth hormone (GH)...

Cite
Melkersson K, Hulting AL, Hall K. Hormonal evaluation in schizophrenic patients treated with neuroleptics. Neuro Endocrinol Lett. 1999;20(3):199-204
Melkersson, K., Hulting, A. L., & Hall, K. (1999). Hormonal evaluation in schizophrenic patients treated with neuroleptics. Neuro endocrinology letters, 20(3), 199-204.
Melkersson, Kristina, et al. "Hormonal evaluation in schizophrenic patients treated with neuroleptics." Neuro endocrinology letters vol. 20,3 (1999): 199-204.
Melkersson K, Hulting AL, Hall K. Hormonal evaluation in schizophrenic patients treated with neuroleptics. Neuro Endocrinol Lett. 1999;20(3):199-204. PMID: 11462115.
Copy Download .nbib Format: NLM
Immunodetection of Insulin-Like Growth Factor I (IGF-l) in Normal and Pathological Adrenocortical Tissue.

Endocrine pathology

Faical S, Maciel RM, Nose-Alberti V, Santos MC, Kater CE.
PMID: 12114663
Endocr Pathol. 1998;9(1):63-70. doi: 10.1007/BF02739953.

IGF-I is one of the peptides that participates in normal adrenocortical cell growth and, possibly, in the genesis and/or maintenance of tumors and hyperplasias of the adrenal cortex. An immunohistochemical technique was used for the analysis of IGF-l expression...

Cite
Faical S, Maciel RM, Nose-Alberti V, et al. Immunodetection of Insulin-Like Growth Factor I (IGF-l) in Normal and Pathological Adrenocortical Tissue. Endocr Pathol. 1998;9(1):63-70doi: 10.1007/BF02739953.
Faical, S., Maciel, R. M., Nose-Alberti, V., Santos, M. C., & Kater, C. E. (1998). Immunodetection of Insulin-Like Growth Factor I (IGF-l) in Normal and Pathological Adrenocortical Tissue. Endocrine pathology, 9(1), 63-70. https://doi.org/10.1007/BF02739953
Faical, Samir, et al. "Immunodetection of Insulin-Like Growth Factor I (IGF-l) in Normal and Pathological Adrenocortical Tissue." Endocrine pathology vol. 9,1 (1998): 63-70. doi: https://doi.org/10.1007/BF02739953
Faical S, Maciel RM, Nose-Alberti V, Santos MC, Kater CE. Immunodetection of Insulin-Like Growth Factor I (IGF-l) in Normal and Pathological Adrenocortical Tissue. Endocr Pathol. 1998;9(1):63-70. doi: 10.1007/BF02739953. PMID: 12114663.
Copy Download .nbib Format: NLM
Insulin-like growth factor-I promotes nerve regeneration through a nerve graft in an experimental model of facial paralysis.

Restorative neurology and neuroscience

Thanos PK, Okajima S, Tiangco DA, Terzis JK.
PMID: 12671244
Restor Neurol Neurosci. 1999;15(1):57-71.

Among the pathological sequelae of facial paralysis is a paralytic eye. Apart from the psychological and aesthetic deficits, facial paralysis if left untreated can lead to dryness, ulceration and eventual blindness. Although numerous restorative microsurgical approaches have been introduced...

Cite
Thanos PK, Okajima S, Tiangco DA, et al. Insulin-like growth factor-I promotes nerve regeneration through a nerve graft in an experimental model of facial paralysis. Restor Neurol Neurosci. 1999;15(1):57-71
Thanos, P. K., Okajima, S., Tiangco, D. A., & Terzis, J. K. (1999). Insulin-like growth factor-I promotes nerve regeneration through a nerve graft in an experimental model of facial paralysis. Restorative neurology and neuroscience, 15(1), 57-71.
Thanos, Panayotis K., et al. "Insulin-like growth factor-I promotes nerve regeneration through a nerve graft in an experimental model of facial paralysis." Restorative neurology and neuroscience vol. 15,1 (1999): 57-71.
Thanos PK, Okajima S, Tiangco DA, Terzis JK. Insulin-like growth factor-I promotes nerve regeneration through a nerve graft in an experimental model of facial paralysis. Restor Neurol Neurosci. 1999;15(1):57-71. PMID: 12671244.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 508 entries